Storia in 2 fonti

For pancreatic cancer patients, an exciting drug can feel out of reach

For pancreatic cancer patients, the surge in interest for an exciting new drug is leaving them fearful about when they might get the treatment or if there will be enough to go around.

Raccontata da

pbs.org

statnews.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

statnews.comStai leggendo14 h fa

For pancreatic cancer patients, an exciting drug can feel out of reach

For pancreatic cancer patients, the surge in interest for an exciting new drug is leaving them fearful about when they might get the treatment or if there will be enough to go around.

originale

pbs.org3 g fa

Promising new treatment for pancreatic cancer doubles survival rates

Daraxonrasib doubled pancreatic cancer survival to 13 months versus 6 months, targeting KRAS mutations. With >90% of pancreatic cancers carrying KRAS mutations and applicability to lung and colon tumors, this reshapes precision-oncology investment thesis.

Leggi questa versione → originale

For pancreatic cancer patients, an exciting drug can feel out of reach

Confronto fonti

For pancreatic cancer patients, an exciting drug can feel out of reach

Promising new treatment for pancreatic cancer doubles survival rates

Timeline cronologica

Promising new treatment for pancreatic cancer doubles survival rates

For pancreatic cancer patients, an exciting drug can feel out of reach

For pancreatic cancer patients, an exciting drug can feel out of reach

Confronto fonti

For pancreatic cancer patients, an exciting drug can feel out of reach

Promising new treatment for pancreatic cancer doubles survival rates

Timeline cronologica

Promising new treatment for pancreatic cancer doubles survival rates

For pancreatic cancer patients, an exciting drug can feel out of reach